Differentiation induction with pioglitazone in tumors In an animal model on breast cancer, it could be shown that the combination of pioglitazone with a MEK inhibitor may induce tumor differentiation, transdifferentiation of tumor cells to adipocytes by epithelial-mesenchymal transission (42, 157). This evidence concerns the gene MAP2K7 and breast cancer.